Optical isomers
    11.
    发明授权
    Optical isomers 失效
    光学异构体

    公开(公告)号:US4981858A

    公开(公告)日:1991-01-01

    申请号:US339888

    申请日:1989-04-18

    IPC分类号: C07D497/20

    CPC分类号: C07D497/20

    摘要: The (+)-cis-, (-)-cis-, (+)-trans- and (-)-trans- forms of 2-methylspiro(1,3-oxathiolan-5,3')quinuclidine are prepared by optical resolution of each of the (.+-.)-cis- and (.+-.)-trans-isomers. These compounds find application in treating diseases of the central nervous system in mammals, especially diseases due to a deficiency in the central cholinergic system. Biological tests indicate that the (-)-cis-form, as well as the (.+-.)-cis-isomer, shows particular promise for treating senile dementia of Alzheimer's type.

    摘要翻译: 2-甲基螺(1,3-氧硫杂环戊烷-5,3')奎宁环的(+) - 顺 - ,( - ) - 顺 - ,(+) - 反 - 和( - ) - 每个(+/-) - 顺式和(+/-) - 反式异构体的分辨率。 这些化合物可用于治疗哺乳动物中枢神经系统疾病,特别是由于中枢胆碱能系统缺乏引起的疾病。 生物试验表明( - ) - 顺式和(+/-)顺式异构体显示出治疗老年痴呆症老年痴呆症的特殊希望。

    Compositions and Methods for the Treatment of Xerostomia

    公开(公告)号:US20200040003A1

    公开(公告)日:2020-02-06

    申请号:US16339431

    申请日:2017-04-19

    发明人: Mahesh Kandula

    摘要: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.

    PROCESS FOR PRODUCTION OF QUINUCLIDINE COMPOUNDS
    16.
    发明申请
    PROCESS FOR PRODUCTION OF QUINUCLIDINE COMPOUNDS 审中-公开
    喹啉化合物的生产工艺

    公开(公告)号:US20130060036A1

    公开(公告)日:2013-03-07

    申请号:US13503382

    申请日:2010-10-21

    IPC分类号: C07D497/20

    摘要: Provided is a production method for a cis-QMF, which has a low environmental burden and is industrially advantageous. Specifically provided is a production method for a cis-type 2-alkylspiro(1,3-oxathiolane-5,3′)quinuclidine hydrochloride, including: reacting a cis-trans isomer mixture of 2-alkylspiro(1,3-oxathiolane-5,3′)quinuclidine with p-nitrobenzoic acid; resolving the resultant product to produce a cis-type 2-alkylspiro(1,3-oxathiolane-5,3′)quinuclidine p-nitrobenzoate; and converting the p-nitrobenzoate into a hydrochloride.

    摘要翻译: 提供了具有低环境负荷并且在工业上有利的顺式-QMF的制备方法。 具体提供的是顺式2-烷基螺(1,3-氧硫杂环戊烷-5,3')奎宁环酸盐酸盐的制备方法,包括:使2-烷基螺(1,3-氧硫杂环戊烷-5 ,3')奎宁环与对硝基苯甲酸; 分解所得产物以产生对 - 硝基苯甲酸顺式-2-烷基螺(1,3-氧硫杂环戊烷-5,3')奎宁环; 并将对硝基苯甲酸酯转化成盐酸盐。

    Pyridomorphinans, thienomorphinans and use thereof
    17.
    发明授权
    Pyridomorphinans, thienomorphinans and use thereof 有权
    吡哆醇,噻吩吗啡喃及其用途

    公开(公告)号:US07015326B1

    公开(公告)日:2006-03-21

    申请号:US10049504

    申请日:2000-08-14

    IPC分类号: C07D497/20

    CPC分类号: C07D495/20

    摘要: Compounds represented by the formulae: wherein each of Y, X and R individually is selected from the group consisting of hydrogen hydroxy, halo, CF3, NO2, CN, NH2, COR1 and CO2R2 wherein R1 is selected from the group consisting of alkyl, aryl, alkaryl, and NH2, and R2 is selected from the group consisting of alkyl aryl, and aralkyl, and provided that at least one of Y, X and R in formula I is other than hydrogen; and pharmaceutically acceptable salts thereof are provided along with uses as immunodulaters and/or treating for drug abuse and/or as analegesics for treating pain.

    摘要翻译: 由下式表示的化合物:其中Y,X和R各自独立地选自羟基,卤素,CF 3,NO 2,CN,NH 其中R 1选自:其中R 1,R 2,R 2,R 2, 由烷基,芳基,烷芳基和NH 2 2和R 2 2组成的组选自烷基芳基和芳烷基,并且条件是至少一个 式I中的Y,X和R不是氢; 及其药学上可接受的盐与免疫力学和/或用于药物滥用的治疗用途和/或用于治疗疼痛的治疗剂一起提供。

    Novel hindered spiro-ketal nitroxides
    18.
    发明申请
    Novel hindered spiro-ketal nitroxides 审中-公开
    新型阻碍螺缩酮的氮氧化物

    公开(公告)号:US20030009031A1

    公开(公告)日:2003-01-09

    申请号:US09844986

    申请日:2001-04-30

    IPC分类号: C07D497/20

    CPC分类号: C07D491/10

    摘要: The present invention discloses a series of novel hindered spiro-ketal nitroxides prepared by the ketalization reaction of 1,3-propanediols with triacetoneamine followed by oxidation. This invention also shows that these novel spiro-nitroxides are capable of inhibiting vinyl and acrylate polymerizations using an effective inhibition concentration of the nitroxide of the present invention.

    摘要翻译: 本发明公开了通过1,3-丙二醇与三丙酮胺的缩酮化反应制备的一系列新型受阻螺 - 缩酮氮氧自由基,然后氧化。 本发明还表明,这些新的螺 - 氮氧化物能够使用本发明的氮氧化物的有效抑制浓度来抑制乙烯基和丙烯酸酯聚合。

    Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine
and method of treating senile dementia
    19.
    发明授权
    Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia 失效
    包含螺恶唑硫酮/奎宁环的药物组合物和治疗老年痴呆的方法

    公开(公告)号:US5106831A

    公开(公告)日:1992-04-21

    申请号:US599977

    申请日:1990-10-19

    IPC分类号: C07D497/20

    CPC分类号: C07D497/20

    摘要: A pharmaceutical composition is disclosed comprising (-)-cis-2-methylspiro(1,3-oxathiolan-5,3')quinuclidine, and/or the pharmaceutically compatible acid addition salts thereof, together with at least one of physostigmine, tetrahydroaminoacridine, choline, lecithin, piracetam, aniracetam, pramiracetam, oxiracetam, 4-aminopyridine, 3,4-diaminopyridine, somatostatin, pirenzepine, N-methylatropine, N-butylscopolamine, scopolamine, clonidine, quanfamicine and Nerve Growth Factor. Also disclosed is a method for treating senile dementia of Alzheimer's type, which comprises coadministering to a patient in need thereof an effective dose of the spiro compound together with at least one other compound selected from those listed above.

    摘要翻译: 公开了一种药物组合物,其包含( - ) - 顺式-2-甲基螺旋(1,3-氧硫杂环戊烷-5,3')奎宁环和/或其药学上相容的酸加成盐,以及至少一种毒扁豆素,四氢氨基吖啶, 胆碱,卵磷脂,吡拉西坦,阿拉西坦,普拉西坦,奥拉西坦,4-氨基吡啶,3,4-二氨基吡啶,生长抑素,哌仑西平,N-甲基阿托品,N-丁基东莨菪碱,东莨菪碱,可乐定,喹唑啉和神经生长因子。 还公开了一种治疗阿尔茨海默氏型老年痴呆症的方法,其包括将有效剂量的螺环化合物与选自上述列举的至少一种其它化合物共同施用于有需要的患者。

    Process for labelling sulfur-containing compounds
    20.
    发明授权
    Process for labelling sulfur-containing compounds 失效
    含硫化合物标记方法

    公开(公告)号:US4900830A

    公开(公告)日:1990-02-13

    申请号:US114479

    申请日:1987-10-28

    IPC分类号: C07D497/20

    CPC分类号: C07D497/20

    摘要: The invention thus provides a process for obtaining the preferential replacement by isotopes, of at least one of the hydrogen atoms selected from the group consisting of those attached to the .alpha.- or .alpha.'-carbon atoms in a compound containing the structural moiety (I) ##STR1## which comprises the steps of oxidizing the compound to the corresponding sulfoxide or sulfone which contains the corresponding structural moiety (II) ##STR2## wherein in the sulfoxide n is 1 and in the sulfone n is 2, effecting the isotopic replacement by a known method of said at least one hydrogen atom, and reducing the resultant isotope-labelled sulfoxide or sulfone to the correspondingly labelled compound containing the structural moiety (I).

    摘要翻译: 因此,本发明提供了一种通过同位素获得优先置换的方法,该方法中至少一个氢原子选自与含有结构部分(I)的化合物中的α-或α-碳原子连接的氢原子, 其包括将化合物氧化成相应的亚砜或砜的步骤,所述亚砜或砜包含相应的结构部分(II),其中在亚砜中n为1,在砜中n为2, 通过所述至少一个氢原子的已知方法实现同位素替代,并将所得到的同位素标记的亚砜或砜还原成含有结构部分(I)的相应标记的化合物。